EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

LegoChem Biosciences Inc (141080) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of LegoChem Biosciences Inc KRW 8,980, price KRW 82,300, upside -89.1%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7141080002

LB Thin data Sep 24, 2026

LegoChem Biosciences Inc

141080 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 8,980 KRW · Strongly overvalued (−89.1%)
!Quality 35/100
!Expensive Growth (revenue 5y +23.4 %/yr)
!Loss-making · -109.7% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/9)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch LegoChem Biosciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

213,500 KRW 30,650 KRW Fair Value 8,980 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 30,650 KRW – 213,500 KRW · fair‑value band 5,927 KRW – 11,225 KRW · the 82,300 KRW price screens above the 8,980 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow LegoChem Biosciences in your weekly email

Every Wednesday you see whether LegoChem Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs.

Show more

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Stock analysis

LegoChem Biosciences Inc (141080) currently trades at 82,300 KRW, while our model-based Fair Value estimate is 8,980 KRW, 89.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Scenario range: 5,927 KRW (bear) to 11,225 KRW (bull), the price of 82,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

LegoChem Biosciences Inc reported revenue of 142B KRW in FY2025 versus 32.2B KRW in FY2021, a compound +44.8%/yr. Reported net income was −74.3B KRW in FY2025.

Key figures

Market cap 4.4T KRW (≈ $3.3B) · P/S ratio 34.8 · Net margin −52.5% · Return on equity −28.3% · Return on assets (EBIT) −18.0% · Operating margin −104% · Revenue (TTM) 126B KRW · Revenue growth (YoY) −30.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −89%, 141080 screens richer than that median.

Fair Value models

Bear 5,927 KRW Fair Value 8,980 KRW Bull 11,225 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 6,965 KRW 9,333 KRW 13,930 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 6,965 KRW 9,333 KRW 13,930 KRW 54

Open the full fair value analysis →

Notify me when 141080 reaches fair value

Put 141080 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 35/100

Of which business quality 40 · Market factors (momentum, volatility) 15

Profitability 7
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 26
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 29
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 38
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.4%
Start year 2020 (pandemic). Over 10 years: +54.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−59.7% (2020) → −75.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

141080 screens overvalued: fair value 89% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare LegoChem Biosciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −89.1% · Bottom 25%
Profitability
Return on assets −13.9% · Below median
Net margin (TTM) −109.7% · Bottom 25%
Operating margin (TTM) −104.3% · Bottom 25%
Growth and dividend
Revenue growth −30.4% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.03× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LegoChem Biosciences Inc · Fair Value
8,980 KRW −89%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "LegoChem Biosciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/141080

Frequently asked questions

Is LegoChem Biosciences Inc (141080) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 8,980 KRW versus a price of 82,300 KRW, about −89% upside (overvalued).
What is the fair value of 141080?
Our model-based fair value for LegoChem Biosciences Inc is 8,980 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 82,300 KRW.
What is the quality score of 141080?
LegoChem Biosciences Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LegoChem Biosciences Inc (141080)?
Our model-based price target is the fair value of 8,980 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 5,927 KRW, optimistic scenario 11,225 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the LegoChem Biosciences Inc stock forecast for 2026?
Our models put fair value at 8,980 KRW, about −89% upside versus a price of 82,300 KRW (overvalued). Cautious scenario 5,927 KRW, optimistic scenario 11,225 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of LegoChem Biosciences Inc (141080)?
LegoChem Biosciences Inc reported trailing-twelve-month revenue of about 126B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of LegoChem Biosciences Inc (141080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LegoChem Biosciences Inc it is 8,980 KRW per share (as of Sep 24, 2026), against a price of 82,300 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is LegoChem Biosciences Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 141080 trades above its calculated fair value: price 82,300 KRW, fair value 8,980 KRW, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 141080?
No. The price is what the market pays today (82,300 KRW); the fair value is what the company's own numbers justify (8,980 KRW). For LegoChem Biosciences Inc the two are 73,320 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is LegoChem Biosciences Inc worth?
The market values LegoChem Biosciences Inc at about 4.4T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 82,300 KRW; our models calculate a fair value of 8,980 KRW per share.
What do the bullish and bearish scenarios say about 141080?
Our models span a range for LegoChem Biosciences Inc: cautious scenario 5,927 KRW, base 8,980 KRW, optimistic 11,225 KRW per share (as of Sep 24, 2026, price 82,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LegoChem Biosciences Inc (141080)?
Balance-sheet figures for LegoChem Biosciences Inc (as of Sep 24, 2026): return on equity −28.3%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 141080 from its 52-week high?
LegoChem Biosciences Inc trades at 82,300 KRW, about 61% below its 52-week high of 213,500 KRW and 6% above the low of 77,900 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 8,980 KRW is for.
Which stocks are comparable to LegoChem Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LegoChem Biosciences Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 82,300 KRW, calculated fair value 8,980 KRW (−89%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 141080 calculated?
We run LegoChem Biosciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 8,980 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. LegoChem Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LegoChem Biosciences Inc (141080)?
The closing price on Oct 2, 2026 was 82,300 KRW. Our model-based fair value is 8,980 KRW, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LegoChem Biosciences Inc right now?
The price sits above even our optimistic bull case (11,225 KRW). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (5,927 KRW to 11,225 KRW) leaves room in how you read the outcome.

Key figures of LegoChem Biosciences Inc

How large is the market capitalisation of LegoChem Biosciences Inc (141080)?
The market capitalisation of LegoChem Biosciences Inc is 4.4T KRW (≈ $3.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LegoChem Biosciences Inc (141080)?
The price-to-sales ratio of LegoChem Biosciences Inc is 34.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of LegoChem Biosciences Inc (141080)?
The net margin of LegoChem Biosciences Inc is −52.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LegoChem Biosciences Inc (141080)?
The return on equity (ROE) of LegoChem Biosciences Inc is −28.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LegoChem Biosciences Inc (141080)?
On an EBIT basis the return on assets of LegoChem Biosciences Inc is −18.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LegoChem Biosciences Inc (141080)?
The operating margin of LegoChem Biosciences Inc is −104% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LegoChem Biosciences Inc (141080)?
Revenue at LegoChem Biosciences Inc is growing −30.4% versus a year earlier (3y avg +61.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LegoChem Biosciences Inc (141080)?
Earnings per share at LegoChem Biosciences Inc are growing +118% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does LegoChem Biosciences Inc (141080) generate?
The free cash flow of LegoChem Biosciences Inc is −131B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch LegoChem Biosciences Inc in the live analysis

One click puts LegoChem Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.